Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Regenxbio (RGNX) Non Operating Income (2016 - 2025)

Historic Non Operating Income for Regenxbio (RGNX) over the last 12 years, with Q3 2025 value amounting to -$9.5 million.

  • Regenxbio's Non Operating Income fell 48411.93% to -$9.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$23.0 million, marking a year-over-year decrease of 43196.13%. This contributed to the annual value of $6.2 million for FY2024, which is 3931.28% up from last year.
  • Latest data reveals that Regenxbio reported Non Operating Income of -$9.5 million as of Q3 2025, which was down 48411.93% from -$7.6 million recorded in Q2 2025.
  • In the past 5 years, Regenxbio's Non Operating Income registered a high of $3.1 million during Q3 2023, and its lowest value of -$9.5 million during Q3 2025.
  • Moreover, its 5-year median value for Non Operating Income was -$2.2 million (2022), whereas its average is -$2.6 million.
  • In the last 5 years, Regenxbio's Non Operating Income surged by 20269.75% in 2024 and then crashed by 123395.87% in 2025.
  • Regenxbio's Non Operating Income (Quarter) stood at -$6.2 million in 2021, then soared by 64.23% to -$2.2 million in 2022, then surged by 139.06% to $862000.0 in 2023, then tumbled by 78.89% to $182000.0 in 2024, then plummeted by 5336.26% to -$9.5 million in 2025.
  • Its Non Operating Income stands at -$9.5 million for Q3 2025, versus -$7.6 million for Q2 2025 and -$6.0 million for Q1 2025.